ADAM17 and COVID-19: Indeed, inhibiting ACE2 or the metalloprotease ADAM17 that is responsible for ACE2 shedding could be an effective way to block the overactivation of the RAS axes, which in turn would lead to the suppression of the inflammatory responses in COVID-19 and attenuate severe lung injury [61,120].